168 related articles for article (PubMed ID: 24334029)
1. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
2. Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131).
Mimoto F; Katada H; Kadono S; Igawa T; Kuramochi T; Muraoka M; Wada Y; Haraya K; Miyazaki T; Hattori K
Protein Eng Des Sel; 2013 Oct; 26(10):589-98. PubMed ID: 23744091
[TBL] [Abstract][Full Text] [Related]
3. A general Fc engineering platform for the next generation of antibody therapeutics.
Chen D; Zhao Y; Li M; Shang H; Li N; Li F; Wang W; Wang Y; Jin R; Liu S; Li X; Gao S; Tian Y; Li R; Li H; Zhang Y; Du M; Cao Y; Zhang Y; Li X; Huang Y; Hu LA; Li F; Zhang H
Theranostics; 2021; 11(4):1901-1917. PubMed ID: 33408788
[No Abstract] [Full Text] [Related]
4. Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal antibodies.
Yu X; Baruah K; Harvey DJ; Vasiljevic S; Alonzi DS; Song BD; Higgins MK; Bowden TA; Scanlan CN; Crispin M
J Am Chem Soc; 2013 Jul; 135(26):9723-32. PubMed ID: 23745692
[TBL] [Abstract][Full Text] [Related]
5. Structural characterization of a human Fc fragment engineered for lack of effector functions.
Oganesyan V; Gao C; Shirinian L; Wu H; Dall'Acqua WF
Acta Crystallogr D Biol Crystallogr; 2008 Jun; 64(Pt 6):700-4. PubMed ID: 18560159
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans.
Mizushima T; Yagi H; Takemoto E; Shibata-Koyama M; Isoda Y; Iida S; Masuda K; Satoh M; Kato K
Genes Cells; 2011 Nov; 16(11):1071-80. PubMed ID: 22023369
[TBL] [Abstract][Full Text] [Related]
7. rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.
Spirig R; Campbell IK; Koernig S; Chen CG; Lewis BJB; Butcher R; Muir I; Taylor S; Chia J; Leong D; Simmonds J; Scotney P; Schmidt P; Fabri L; Hofmann A; Jordi M; Spycher MO; Cattepoel S; Brasseit J; Panousis C; Rowe T; Branch DR; Baz Morelli A; Käsermann F; Zuercher AW
J Immunol; 2018 Apr; 200(8):2542-2553. PubMed ID: 29531170
[TBL] [Abstract][Full Text] [Related]
8. Evidence of variable human Fcγ receptor-Fc affinities across differentially-complexed IgG.
Crowley AR; Mehlenbacher MR; Sajadi MM; DeVico AL; Lewis GK; Ackerman ME
MAbs; 2023; 15(1):2231128. PubMed ID: 37405954
[TBL] [Abstract][Full Text] [Related]
9. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
White AL; Chan HT; French RR; Beers SA; Cragg MS; Johnson PW; Glennie MJ
Cancer Immunol Immunother; 2013 May; 62(5):941-8. PubMed ID: 23543215
[TBL] [Abstract][Full Text] [Related]
10. Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity.
Chenoweth AM; Esparon S; Wines BD; Schuurman J; Labrijn AF; Hogarth PM
Immunol Cell Biol; 2023 Aug; 101(7):657-662. PubMed ID: 36997299
[TBL] [Abstract][Full Text] [Related]
11. The Structural Role of Antibody N-Glycosylation in Receptor Interactions.
Subedi GP; Barb AW
Structure; 2015 Sep; 23(9):1573-1583. PubMed ID: 26211613
[TBL] [Abstract][Full Text] [Related]
12. Engineering the interactions between a plant-produced HIV antibody and human Fc receptors.
Stelter S; Paul MJ; Teh AY; Grandits M; Altmann F; Vanier J; Bardor M; Castilho A; Allen RL; Ma JK
Plant Biotechnol J; 2020 Feb; 18(2):402-414. PubMed ID: 31301102
[TBL] [Abstract][Full Text] [Related]
13. Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity.
Smith AJ; Thurman RE; Zeng W; Grogan B; Lucas S; Gutierrez G; Heiser RA; Wo SW; Blackmarr A; Peterson S; Gardai SJ
Front Immunol; 2023; 14():1280986. PubMed ID: 38022590
[TBL] [Abstract][Full Text] [Related]
14. Benchmarking glycoform-resolved affinity separation - mass spectrometry assays for studying FcγRIIIa binding.
Gstöttner C; Lippold S; Hook M; Yang F; Haberger M; Wuhrer M; Falck D; Schlothauer T; Domínguez-Vega E
Front Immunol; 2024; 15():1347871. PubMed ID: 38469305
[TBL] [Abstract][Full Text] [Related]
15. An antibody with Fab-constant domains exchanged for a pair of CH3 domains.
Wozniak-Knopp G; Stadlmayr G; Perthold JW; Stadlbauer K; Gotsmy M; Becker S; Rüker F
PLoS One; 2018; 13(4):e0195442. PubMed ID: 29630643
[TBL] [Abstract][Full Text] [Related]
16. Decoding human-macaque interspecies differences in Fc-effector functions: The structural basis for CD16-dependent effector function in Rhesus macaques.
Tolbert WD; Gohain N; Kremer PG; Hederman AP; Nguyen DN; Van V; Sherburn R; Lewis GK; Finzi A; Pollara J; Ackerman ME; Barb AW; Pazgier M
Front Immunol; 2022; 13():960411. PubMed ID: 36131913
[TBL] [Abstract][Full Text] [Related]
17. Diversification of IgG effector functions.
Bournazos S; Ravetch JV
Int Immunol; 2017 Jul; 29(7):303-310. PubMed ID: 28472280
[TBL] [Abstract][Full Text] [Related]
18. IgG and Fcγ Receptors in Intestinal Immunity and Inflammation.
Castro-Dopico T; Clatworthy MR
Front Immunol; 2019; 10():805. PubMed ID: 31031776
[TBL] [Abstract][Full Text] [Related]
19. Optimizing pH response of affinity between protein G and IgG Fc: how electrostatic modulations affect protein-protein interactions.
Watanabe H; Matsumaru H; Ooishi A; Feng Y; Odahara T; Suto K; Honda S
J Biol Chem; 2009 May; 284(18):12373-83. PubMed ID: 19269963
[TBL] [Abstract][Full Text] [Related]
20. A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies.
Bailey MJ; Broecker F; Leon PE; Tan GS
J Vis Exp; 2018 Feb; (132):. PubMed ID: 29553549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
